DNDi South Asia

 
 

DNDi South Asia

 

DNDi started its activities in South Asia in 2004 to build and strengthen regional partnerships to carry out R&D for neglected diseases in the region. DNDi has activities in India and Bangladesh, mainly focused on visceral leishmaniasis and conducting clinical trials and capacity-building initiatives. More recently, DNDi South Asia started to be active in the fields of paediatric HIV and early drug discovery for leishmaniasis. Read highlights from our research activities in 2019

Projects

DNDi South Asia

Cover page DNDi in India Brochure released in 2019

English
2019

 

 

DNDi South Asia

PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
India

Tel: +91 11 4550 1795

 

Highlights

2018

  • Supported the Indian National Kala-azar Elimination Programme in building capacity to diagnose kala-azar (visceral leishmaniasis) and post-kala-azar dermal leishmaniasis (PKDL), and by gathering evidence needed to respond to threats to the sustainable elimination of visceral leishmaniasis in the region.
  • Completed recruitment for a clinical trial for PKDL, testing amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected by mid-2020.
  • Partnered in an MSF study on kala-azar-HIV co-infection in Bihar state to evaluate treatments with amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected in 2019 that will provide key evidence to national and regional decision-makers on the best treatment for co-infected patients.
  • Launched GARDP’s 11-country observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns.